OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an...
OpenAI has acquired a drug development platform to help pharmaceutical teams coordinate research programs and manage delays.
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from...
The companies plan to develop AI agents that connect scientific findings with the studies, decisions, and workflows to advance drug candidates.
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
First reported:
First saved on ClustZ:
Coverage updated:
We use cookies to improve your experience and analyze site traffic. By clicking "Accept", you agree to our use of cookies. See our Privacy Policy.